Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy.

Blood Cancer J · 2023 · PMC10412575 · PMID 37558706

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

While patients receiving ide-cel within six months of their last BCMA-TT exposure had a numerically lower ORR (60% versus 83%; p = 0.076) and best response of CR or better (20% versus 35%; p = 0.48) compared to the patients receiving ide-cel >6 months after their last BCMA-TT exposure, this did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.